Fundraising Fox

BioStem Technologies

OTC: BSEM

Pompano Beach, US · Florida corporation

biostemtechnologies.com ↗

BioStem Technologies develops, manufactures, and commercializes perinatal tissue-based allografts for regenerative therapies, using its proprietary BioRetain processing method to preserve the tissue's biological properties. Products are made in an AATB-accredited, FDA-registered, cGMP-compliant lab and serve the regenerative medicine market.

BiotechHealthtechMedical Devices

Founders & leadership

AV
Andrew Van VurstExecutive Officer, Director
BP
Brandon PoeExecutive Officer
KW
Kenneth WarringtonDirector
JU
Jodi UngrodtDirector
KG
Katherine GorrellExecutive Officer
TJ
Thomas J. DuganDirector
PD
Patrick DalyDirector
BH
Barry HassettExecutive Officer
JM
Jason MatuszewskiExecutive Officer, Director

Competitors · 4

by search overlap
Diabetes Prevention Program163 shared keywords
Dervan et al122 shared keywords
ResearchGate119 shared keywords
Net Health113 shared keywordsNet Health provides specialized EHR software and clinical analytics for healthcare providers in specialty areas including wound care, rehab therapy, skilled nursing/value-based care, and occupational health. Its products cover clinical documentation, compliance and billing, patient engagement, predictive analytics, and mobile wound imaging for medical professionals across the continuum of care.

Companies competing with BioStem Technologies for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements
▶$2.5MraisedJun 2026 · 1 investors · Biotechnology
Rule 506(b)
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor - BioSpacebiospace.com · May 2026BioStem Technologies (OTC:BSEM) Secures Four Patents, Files for SEC Registrationkalkine.com · Jul 2026
Officers, directors & promoters on the filing
  • Andrew Van VurstExecutive Officer, Director
  • Brandon PoeExecutive Officer
  • Kenneth WarringtonDirector
  • Jodi UngrodtDirector
  • Katherine GorrellExecutive Officer
  • Thomas J. DuganDirector
  • Patrick DalyDirector
  • Barry HassettExecutive Officer
  • Jason MatuszewskiExecutive Officer, Director
Offering amount
$2.5M
Amount sold
$2.5M
First sale
May 2026
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$220KraisedApr 2023 · 5 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Andrew Smith-Van VurstExecutive Officer, Director
  • Jason MatuszewskiExecutive Officer, Director
Offering amount
$5M
Amount sold
$220K
First sale
Mar 2023
Incorporated
Corporation, Florida
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$3MofferedMay 2021 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jason MatuszewskiExecutive Officer, Director
  • Andrew Smith-Van VurstExecutive Officer, Director
Offering amount
$3M
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10KraisedAug 2016 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Jason MatuszewskiExecutive Officer, Director
  • Robert WatsonDirector
  • Andrew VanVurstExecutive Officer, Director
  • Henry VanVurstExecutive Officer, Director
Offering amount
$6M
Amount sold
$10K
First sale
Aug 2016
Incorporated
Corporation, Florida
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$6MofferedFeb 2016 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jason Victor MatuszewskiExecutive Officer
Offering amount
$6M
Minimum investment
$5K
Proceeds to insiders
$185K
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news